(Il Sole 24 Ore Radiocor) - Milano, 31 mar - The US pharmaceutical group Eli Lilly said that it has reached a definitive agreement to acquire Centessa, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions.

Under the terms of the agreement, Eli Lilly will acquire Centessa's share for 38.00 dollars each plus one non-transferrable contingent value right (CVR) that entitles the holder to receive up to an aggregate of 9.00 dollars subject to the achievement of three milestones, for a total potential consideration of up to 47.00 dollars per share.

The upfront cash consideration would be 6.3 billion dollars and the CVR represents an additional potential value of 1.5 billion.

The transaction is expected to close in the third quarter,.

Eli Lilly said.

(RADIOCOR) 31-03-26 14:28:13 (0480) 5 NNNN